Samsung Bioepis Posts Double-Digit Growth with Q1 Sales of 454.9 Billion Won and Operating Profit of 144 Billion Won

Samsung Bioepis recorded 454.9 billion won in revenue and 144 billion won in operating profit in the first quarter of this year, driven by the expansion of global biosimilar sales. These figures represent increases of 14% and 13%, respectively, compared to the same period last year.

Samsung Bioepis Headquarters. Samsung Bioepis

원본보기 아이콘

According to the earnings announcement from Samsung Epis Holdings on April 23, Samsung Bioepis's first-quarter revenue rose by 54.3 billion won and operating profit by 16.1 billion won compared to the same period last year. This performance exceeds the annual revenue growth guidance of "over 10%" presented at the start of the year. A representative from Samsung Bioepis explained, "The company maintained its growth momentum by increasing profits through global biosimilar product sales and expanding its new portfolio."

The company's product and sales strategy is diversifying around two key markets: Europe and the United States. In Europe, Samsung Bioepis is directly selling a total of four products, including the Enbrel biosimilar "SB4," with steady sales maintained across its existing product lineup. For the Eylea biosimilar "SB15," the company is preparing for a launch in Europe in April this year and in the United States in January next year.

In the United States, the Prolia biosimilar "SB16" has emerged as a new growth driver. The product entered the market in January after Samsung Bioepis signed a private label supply agreement with CVS Caremark, one of the top three PBMs in the US. Since then, SB16 has been added to the CVS Caremark preferred drug list, and the company is now focusing on increasing market share and expanding sales.

The partnership strategy has also been accelerated. In March, Samsung Bioepis signed an early-partnership agreement with Sandoz for the research, development, and commercialization of the Entyvio biosimilar "SB36," covering a preclinical-stage pipeline. By integrating expertise from both companies from the early development phase, the aim is to improve the success rate of commercialization.

The company is also accelerating new drug development, with a focus on antibody-drug conjugates (ADCs), which are highlighted as next-generation anticancer therapies. The first ADC drug candidate, "SBE303," entered global Phase 1 clinical trials in March, and on April 20, preclinical data on improved efficacy and safety was released at the American Association for Cancer Research (AACR) 2026. The second candidate, "SBE313," is undergoing preclinical development in collaboration with China's Frontline.

The holding company, Samsung Epis Holdings, also showed an improvement in performance. On a consolidated basis, it posted 453.9 billion won in first-quarter revenue and 90.5 billion won in operating profit, turning to an operating profit in the first quarter since its establishment. This marks a recovery from the operating loss of 63.6 billion won recorded in November and December of last year. Samsung Epis Holdings explained that this turnaround was due to non-cash accounting adjustments, including amortization of PPA development costs.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.